Company registration number 03536427 (England and Wales)
JADE-EURO-MED LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
Affinia
10 - 12 Mulberry Green
Old Harlow
Essex
CM17 0ET
JADE-EURO-MED LIMITED
CONTENTS
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 9
JADE-EURO-MED LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
13,878
22,400
Tangible assets
5
86,236
83,583
100,114
105,983
Current assets
Stocks
516,909
505,578
Debtors
6
379,887
419,789
Cash at bank and in hand
426,109
580,801
1,322,905
1,506,168
Creditors: amounts falling due within one year
7
(421,120)
(541,135)
Net current assets
901,785
965,033
Total assets less current liabilities
1,001,899
1,071,016
Provisions for liabilities
-
(16,080)
Net assets
1,001,899
1,054,936
Capital and reserves
Called up share capital
9
51,420
51,420
Share premium account
456,080
456,080
Profit and loss reserves
494,399
547,436
Total equity
1,001,899
1,054,936
JADE-EURO-MED LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 DECEMBER 2025
31 December 2025
- 2 -

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 8 June 2026 and are signed on its behalf by:
Mr N S Moss
Mr A Newman
Director
Director
Company registration number 03536427 (England and Wales)
JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

Jade-euro-med Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 14 East Hanningfield Industrial Est, Old Church Road, Chelmsford, Essex, CM3 8AB.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover comprises of the sale of body worn continence supplies provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts.

Turnover is recognised when performance obligations are satisfied and the control of goods is transferred to the buyer. Where the performance obligation is satisfied over time, turnover is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of turnover are as follows:

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
Straight line over 5 years
JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
4 years straight line
Plant and equipment
15% reducing balance
Fixtures and fittings
15% reducing balance
Computers
15% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 6 -
1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Stock impairment

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
21
23
4
Intangible fixed assets
Other
£
Cost
At 1 January 2025 and 31 December 2025
42,609
Amortisation and impairment
At 1 January 2025
20,209
Amortisation charged for the year
8,522
At 31 December 2025
28,731
Carrying amount
At 31 December 2025
13,878
At 31 December 2024
22,400
JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
5
Tangible fixed assets
Leasehold improvements
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 January 2025
76,704
86,345
32,711
148,883
37,975
382,618
Additions
35,800
5,240
-
0
3,944
-
0
44,984
Disposals
-
0
-
0
(6,704)
(17,855)
(37,975)
(62,534)
At 31 December 2025
112,504
91,585
26,007
134,972
-
0
365,068
Depreciation and impairment
At 1 January 2025
76,704
76,577
24,545
104,743
16,466
299,035
Depreciation charged in the year
8,950
1,839
1,181
6,718
-
0
18,688
Eliminated in respect of disposals
-
0
-
0
(6,414)
(16,011)
(16,466)
(38,891)
At 31 December 2025
85,654
78,416
19,312
95,450
-
0
278,832
Carrying amount
At 31 December 2025
26,850
13,169
6,695
39,522
-
0
86,236
At 31 December 2024
-
0
9,768
8,166
44,140
21,509
83,583
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
370,269
402,849
Other debtors
9,618
16,940
379,887
419,789
7
Creditors: amounts falling due within one year
2025
2024
£
£
Obligations under finance leases
-
0
15,116
Other borrowings
15,770
4,953
Trade creditors
336,306
433,467
Taxation and social security
59,752
78,168
Accruals and deferred income
9,292
9,431
421,120
541,135

Assets under hire purchase and finance lease arrangements are secured on the assets concerned.

JADE-EURO-MED LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
8
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

Liabilities
Liabilities
2025
2024
Balances:
£
£
Accelerated capital allowances
-
16,080
2025
Movements in the year:
£
Liability at 1 January 2025
16,080
Credit to profit or loss
(16,080)
Liability at 31 December 2025
-

9
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
51,420
51,420
51,420
51,420

The ordinary shares carry equal rights in relation to voting, participating in dividends and the distribution of capital in winding up the company.

10
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
30,544
33,741
11
Directors' transactions

During the year the spouse of one of the directors, made a loan to the company amounting to £35,000. At the end of the year the amount outstanding was £15,556 (2024; £Nil).

2025-12-31 2025-01-01 false false false 08 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr B Mackley Mr N S Moss Mr A Newman Mr R J D Orsler Mrs L M Newman 03536427 2025-01-01 2025-12-31 03536427 2025-12-31 03536427 2024-12-31 03536427 core:IntangibleAssetsOtherThanGoodwill 2025-12-31 03536427 core:IntangibleAssetsOtherThanGoodwill 2024-12-31 03536427 core:LeaseholdImprovements 2025-12-31 03536427 core:PlantMachinery 2025-12-31 03536427 core:FurnitureFittings 2025-12-31 03536427 core:ComputerEquipment 2025-12-31 03536427 core:MotorVehicles 2025-12-31 03536427 core:LeaseholdImprovements 2024-12-31 03536427 core:PlantMachinery 2024-12-31 03536427 core:FurnitureFittings 2024-12-31 03536427 core:ComputerEquipment 2024-12-31 03536427 core:MotorVehicles 2024-12-31 03536427 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 03536427 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 03536427 core:ShareCapital 2025-12-31 03536427 core:ShareCapital 2024-12-31 03536427 core:SharePremium 2025-12-31 03536427 core:SharePremium 2024-12-31 03536427 core:RetainedEarningsAccumulatedLosses 2025-12-31 03536427 core:RetainedEarningsAccumulatedLosses 2024-12-31 03536427 core:ShareCapitalOrdinaryShareClass1 2025-12-31 03536427 core:ShareCapitalOrdinaryShareClass1 2024-12-31 03536427 bus:Director2 2025-01-01 2025-12-31 03536427 bus:Director3 2025-01-01 2025-12-31 03536427 core:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 03536427 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-01-01 2025-12-31 03536427 core:LeaseholdImprovements 2025-01-01 2025-12-31 03536427 core:PlantMachinery 2025-01-01 2025-12-31 03536427 core:FurnitureFittings 2025-01-01 2025-12-31 03536427 core:ComputerEquipment 2025-01-01 2025-12-31 03536427 core:MotorVehicles 2025-01-01 2025-12-31 03536427 2024-01-01 2024-12-31 03536427 core:IntangibleAssetsOtherThanGoodwill 2024-12-31 03536427 core:LeaseholdImprovements 2024-12-31 03536427 core:PlantMachinery 2024-12-31 03536427 core:FurnitureFittings 2024-12-31 03536427 core:ComputerEquipment 2024-12-31 03536427 core:MotorVehicles 2024-12-31 03536427 2024-12-31 03536427 core:CurrentFinancialInstruments 2025-12-31 03536427 core:CurrentFinancialInstruments 2024-12-31 03536427 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 03536427 bus:OrdinaryShareClass1 2025-12-31 03536427 bus:OrdinaryShareClass1 2024-12-31 03536427 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 03536427 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 03536427 bus:FRS102 2025-01-01 2025-12-31 03536427 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 03536427 bus:Director1 2025-01-01 2025-12-31 03536427 bus:Director4 2025-01-01 2025-12-31 03536427 bus:CompanySecretary1 2025-01-01 2025-12-31 03536427 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP